A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Disease Sites:

Breast

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Epirubicin, Olaparib, Paclitaxel, Pembrolizumab, sac-TMT

Principal Investigator(s):

Kennedy, Laura

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

02-16-2026

Trial Type:

Treatment

Protocol ID:

VICCBRE24564

National Clinical Trial ID:

NCT06966700

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available